Introduction
- Gaythorpe KAM
- Bhatia S
- Mangal T
- et al.
Following infection, children develop robust humoral and cellular responses to SARS-CoV-2, targeted primarily against the spike protein of the virus, irrespective of whether they develop symptomatic illness or remain asymptomatic after infection.
- Dowell AC
- Butler MS
- Jinks E
- et al.
Additionally, immunity is sustained for at least 12 months, potentially longer than in adults, with evidence of cross-protection against new SARS-CoV-2 variants.
- Dowell AC
- Butler MS
- Jinks E
- et al.
Reinfection following primary SARS-CoV-2 infection is uncommon but has been described mainly in adults, even in the presence of SARS-CoV-2 antibodies.
,
- Fakhroo A
- AlKhatib HA
- Al Thani AA
- Yassine HM
,
- Milne G
- Hames T
- Scotton C
- et al.
Additionally, breakthrough infections have been reported in vaccinated adults, with increasing risk with time since vaccination.
- Milne G
- Hames T
- Scotton C
- et al.
An increased risk of reinfection has also been reported following the emergence of the delta (B.1.617.2) variant, which is more transmissible than previous SARS-CoV-2 variants and able to at least partially evade both natural and vaccine-induced immunity.
- Edara VV
- Pinsky BA
- Suthar MS
- et al.
However, little is known about the rate, risk factors, characteristics, severity, or outcomes of SARS-CoV-2 reinfections in children with the exception of a few case reports in immunocompromised children.
- Marquez L
- Koy T
- Spinler JK
- et al.
,
- Yadav SP
- Wadhwa T
- Thakkar D
- Kapoor R
- Rastogi N
- Sarma S
- Ladhani SN
- Amin-Chowdhury Z
- Davies HG
- et al.
Cases peaked in mid-April and then declined gradually, leading to easing of lockdown measures, including partial reopening of some school class years during June and July, 2020, and full reopening of all school years albeit with strict infection controls in September, 2020.
- Mensah AA
- Sinnathamby M
- Zaidi A
- et al.
Early in the pandemic, testing for SARS-CoV-2 was limited to symptomatic cases in health-care settings, but community testing became available from June, 2020, initially for individuals with typical symptoms of COVID-19 (fever, new-onset cough, or loss of taste or smell) but soon became available for anyone wishing to be tested, with a 7-day rolling average of in excess of 100 000 tests per day by June 28, 2020.
Evidence before this study
We searched PubMed with the terms “COVID-19” or “SARS-CoV-2” with “reinfection” to identify publications in English relating to SARS-CoV-2 reinfections from Jan 1, 2020, to Nov 15, 2021. We did not find national studies with data on reinfection in children with the exception of case reports, which were mainly reports about immunocompromised children.
There were few publications relating to SARS-CoV-2 reinfections, and these related to adults, with no conclusions for reinfections in children. Published studies reported very low rates of reinfection during the first few months after primary infection in adults. COVID-19 vaccines provide effective immune protection against SARS-CoV-2 infection, but recent studies have reported increasing risk of breakthrough infection with time since primary vaccination due to waning immunity. Several SARS-CoV-2 variants, including the beta, gamma, delta, and omicron variants have been shown to partially evade immunity after natural infection and vaccination, potentially increasing the risk of reinfections and breakthrough infections.
Added value of this study
We used national SARS-CoV-2 testing data during the first 19 months of the pandemic to estimate the risk of reinfection in children compared with adults during a period that encompassed both the alpha and the delta variant waves in England. We found that the risk of reinfection tracked with the risk of SARS-CoV-2 exposure and, therefore, closely reflected community infection rates, with most reinfections occurring during the delta variant wave. While acknowledging the limitation of using national testing data, we found that children had a lower risk of reinfection than did adults, and that the risk of reinfection in children increased with age. Reinfections were not associated with severe disease in terms of hospital admissions or intensive care admissions and there were no fatalities within 28 days of reinfection in children.
Implications of all the available evidence
SARS-CoV-2 reinfections are rare in children, especially younger children, and in England, occurred mainly during the delta wave. Reinfections were not associated with more severe disease or fatal outcomes in children. COVID-19 vaccination will provide further protection against primary infections and reinfections in children.
We aimed to assess the risk of SARS-CoV-2 reinfection in children compared with adults, by analysing national testing data for England during the first 19 months of the pandemic, which included the alpha variant wave during the winter of 2020–21 and the delta variant wave during summer 2021.
Results
TableDemographic characteristics of primary SARS-CoV-2 infection and reinfection cases in children up to age 16 years in England, UK
Data are n (%), or n/N (%).
Of the 2343 children with reinfection, 109 (4·7%) were admitted to hospital at either episode (of first or second infection) and 78 (72%) of those hospitalised were identified as having an underlying comorbidity. Hospital admission rates in children with reinfection were similar for the first (64 [2·7%] of 2343) and second infection (57 [2·4%] of 2343) and included 12 children who were admitted to hospital in both infection periods, who all had additional health issues.
While reviewing the ICD-10 codes provided with hospital admission, 77% (49 of 64) and 72% (41 of 57) of children admitted to hospital had other codes unrelated to COVID-19 diagnosis recorded at first and second infection. Additionally, five children were admitted to hospital specifically for injuries during a first COVID-19 infection and a further five during a reinfection. The median age of children admitted to hospital was slightly lower for primary infection cases (11 years, IQR 7–14) than for reinfection cases (13 years, 10–15). The proportion of children reporting asymptomatic infection at the time of testing was higher in reinfection cases than in primary cases (1038 [49·1%] 2113 vs 235 914 [37·0%] of 638 389; p<0·0001).
Admission to an intensive care unit was rare after primary infection (n=7) or reinfection (n=4). Notably, all four children admitted to an ICU following reinfection had also required intensive care during their primary infection. All four children had multiple and severe multisystem co-morbidities and, despite detailed case note review, ascertaining the contribution of SARS-CoV-2 infection to the illness that eventually led to the intensive care admission was not possible.
There were 44 deaths within 28 days of testing positive for SARS-CoV-2 (44 [0·01%] of 688 418 primary infections), with a further nine deaths occurring within 60 days of testing positive or with COVID-19 specified as a cause of death on the death certificate (53 [0·01%] 688 418 primary infections). All deaths occurred following primary infection and there were no deaths within 28 days or 60 days of positive testing for SARS-CoV-2 after reinfection.
Discussion
SARS-CoV-2 reinfections in children were uncommon and closely followed community infection rates in England, with most reinfections occurring during the delta wave in the summer of 2021. Children had a lower risk of reinfection than did adults overall, especially when compared with unvaccinated younger adults. Among children, reinfections were low up to age 6 years and then increased steadily up to age 16 years, broadly consistent with their risk of primary infection. Severe infection in children, as evidenced by hospital admissions or intensive care admissions, was rare following either primary infection or reinfection, with a high prevalence of comorbidities among children admitted to hospital with reinfection and no deaths reported up to 28 days after reinfection episode.
As of Oct 31, 2021, there were only 441 confirmed reinfections with genetically distinct strains in England.
Weekly national influenza and COVID-19 surveillance report. Week 44 report (up to week 43 data).
We used a pragmatic definition applied to surveillance data that allowed sufficient time for clinical recovery and for the initial PCR test to become negative before a second infection was diagnosed to rule out persistent infections, while acknowledging that reinfection might rarely occur within 90 days of primary infection. The population reinfection rates in England increased sharply following the emergence of the omicron variant from November, 2021, onwards. From this point reinfections accounted for increased proportion of all first infections and reinfections in all ages.
SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 33.
- Yasuhara J
- Kuno T
- Takagi H
- Sumitomo N
Our serosurveillance in educational settings estimated that 11·2% of primary school students (age 5–11 years) had been infected with SARS-CoV-2 by June, 2020,
- Ladhani SN
- Baawuah F
- Beckmann J
- et al.
and 12·8% of secondary school students (age 11–16 years) by September, 2020.
- Ladhani SN
- Ireland G
- Baawuah F
- et al.
Thirdly, community testing became more widely available from June, 2020, including for children, but was primarily targeted to symptomatic individuals with typical COVID-19 symptoms (fever, new-onset cough, and loss of taste or smell). Because children are more likely than are adults to develop a mild, transient illness when exposed to SARS-CoV-2 (and therefore, not seek medical attention for testing or treatment) and to develop non-respiratory symptoms,
- Christophers B
- Gallo Marin B
- Oliva R
- Powell WT
- Savage TJ
- Michelow IC
they would potentially be less likely than adults to undergo testing even after community testing was available. Fourthly, national testing data would not include asymptomatic primary infections or reinfections unless individuals were tested because they were concerned over exposure to a case, and children are more likely to be asymptomatic—and therefore, less likely to be tested— than are adults.
- Sah P
- Fitzpatrick MC
- Zimmer CF
- et al.
Fifthly, the introduction of twice-weekly rapid home testing with LFDs for secondary school pupils since March, 2021, will probably have enhanced case ascertainment, including asymptomatic infections, leading to reduced virus introduction and in-school transmission in 11–16 year-olds. Finally, the risk of reinfection is also likely to vary with time since primary infection and with different SARS-CoV-2 variants. However, comparison of relative risks between variants is not possible because they emerged at different times, such that both the number of people with primary infections who became susceptible to reinfection, and the interval between primary infection and reinfection, were far greater during the delta wave in July, 2021, than in the alpha wave in December, 2020.
- Ladhani SN
- Ireland G
- Baawuah F
- et al.
Among school-aged children, testing rates were heavily influenced by school closure due to lockdowns or school term breaks.
Weekly influenza and COVID-19 surveillance graphs.
The national rollout of COVID-19 vaccines from December, 2020, with gradual extension of eligibility down the age groups to those aged 12 and older, also affected comparison of risk and rates over time.
- Edridge AWD
- Kaczorowska J
- Hoste ACR
- et al.
Reinfections have also been reported with SARS-CoV-2, although the risk was previously estimated to be very low during the first few months after primary infection in adults and even lower in children, although data on reinfections are scarce in the paediatric population.
,
- Pilz S
- Chakeri A
- Ioannidis JP
- et al.
,
- Sanchez-Montalva A
- Fernandez-Naval C
- Anton A
- et al.
Our study confirms a lower risk of reinfection in children compared with in adults, especially unvaccinated young adults and, within the childhood age groups, reinfection rates broadly tracked with primary infection rates by age in years except in infants (younger than age 1 year) who had a higher primary infection rate than reinfection rate. This result is likely to be a testing artefact because of screening in newborns for SARS-CoV-2 and as part of infection screens in young infants presenting to hospital with fever or an infectious illness.
- Mileto D
- Fenizia C
- Cutrera M
- et al.
Reinfections might also occur because of waning immunity with time since primary infection; while most children and adults retain high antibody concentrations with virus neutralising activity for at least 12 months after primary infection, they do wane to undetectable concentrations in a small proportion of individuals.
- Dowell AC
- Butler MS
- Jinks E
- et al.
Waning of immunity has also been reported among vaccinated adults, resulting in increasing risk of breakthrough infections with time since vaccination,
- Mizrahi B
- Lotan R
- Kalkstein N
- et al.
although this risk appears to be lower in mRNA-vaccinated adults with previous SARS-CoV-2 infection than in mRNA-vaccinated adults without previous infection.
- Abu-Raddad LJ
- Chemaitelly H
- Ayoub HH
- et al.
- Milne G
- Hames T
- Scotton C
- et al.
In our cohort, reinfection rates were much higher during the delta wave than the alpha wave, which might be because the alpha variant is antigenically similar to previously circulating SARS-CoV-2 strains while the delta variant, like the beta variant, are antigenically distant.
- Dupont L
- Snell LB
- Graham C
- et al.
This observation is consistent with the lower neutralising activity of antibodies after natural infection,
- Dupont L
- Snell LB
- Graham C
- et al.
or vaccination,
- Choi A
- Koch M
- Wu K
- et al.
,
- Noori M
- Nejadghaderi SA
- Arshi S
- et al.
as well as lower vaccine effectiveness after mRNA vaccination
- Lopez Bernal J
- Andrews N
- Gower C
- et al.
against the delta variant than the alpha and previous variants. Reassuringly, previous infection or COVID-19 vaccination (and more so, a combination of the two) have been shown to be highly protective against severe disease and death due to COVID-19, irrespective of the responsible variant, with studies reporting higher rates of asymptomatic infection and mild illness following reinfection than primary infection in the same individuals.
,
- Fakhroo A
- AlKhatib HA
- Al Thani AA
- Yassine HM
,
- Lopez Bernal J
- Andrews N
- Gower C
- et al.
This result was also observed in our cohort of children who were more likely to be asymptomatic with their reinfection than with their primary infection.
SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 34.
omicron possesses multiple new mutations compared with previous SARS-CoV-2 variants, including some in the spike protein, which enhance its ability to further evade both natural and vaccine-induced immunity.
- Kannan S
- Shaik Syed Ali P
- Sheeza A
Omicron’s potential for rapid transmission with a shorter incubation period has led to record numbers of daily reported cases and elevated numbers of reinfection cases in England.
Weekly influenza and COVID-19 surveillance graphs.
Early data from South Africa, where the variant was first identified, reassuringly indicate a decrease in disease severity with the omicron compared with the delta variant,
- Abdullah F
- Myers J
- Basu D
- et al.
which is likely to be due to a combination of factors, including virus characteristics, previous SARS-CoV-2 infection with other variants, and COVID-19 vaccination. Our ongoing national surveillance will continue to monitor the risks, severity, and outcomes of reinfection with this new variant.
Children and COVID-19: State-Level Data Report.
while ICU admissions were rare and less than in primary infection cases, and mainly in those with severe underlying comorbidities. In the UK, COVID-19 mRNA vaccination is recommended for all those aged 12–15 years and at-risk 5–11-year-olds with underlying co-morbidities, which will help reduce their risk of severe disease after primary infection or reinfection.
Who can get a coronavirus (COVID-19) vaccine.
In addition to the limitations already discussed, we did not collect detailed clinical data on all the reinfection cases to assess disease severity compared with primary infection. Among those who had been admitted to hospital, we were unable to distinguish whether the children were admitted because of COVID-19 illness or if the virus was identified incidentally during routine screening of children attending hospital for other illnesses. The emergence of new variants also made it difficult to assess waning of natural immunity over time. We cannot comment on the risk of reinfection with the omicron variant, which emerged after the study period. As children continue to be vaccinated against COVID-19, assessing long-term protection after natural infection will become more difficult. Finally, we did not assess the risk of complications, such as paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, also known as multisystem inflammatory syndrome in children; MIS-C) and long COVID, after primary SARS-CoV-2 infection or reinfection. Further studies are needed to evaluate the risk of such complications after reinfection compared with primary infection in children.
In children younger than 16 years old, the risk of SARS-CoV-2 reinfection is strongly related to the risk of exposure and, therefore, community infection rates. In England, reinfection rates were higher during the delta wave than the alpha wave, most likely the result of a combination of waning immunity over time since primary infection and partial immune evasion by the delta variant compared with the alpha variant. In children, the risk of reinfection increased with age. Most children had mild infection with very low hospital admission rates after primary infection or reinfection. COVID-19 vaccination will help reduce the risk of severe disease and improve outcomes after primary infection and reinfection, especially in children with underlying comorbidities who might have been over-represented among reinfection cases. The emergence of new variants emphasises the importance of ongoing surveillance of reinfections.
AAM, HC, and SNL were involved in the methodology, formal analysis, investigation, data curation, writing the original draft, reviewing and editing the manuscript, designing of tables and graphs, and verified the underlying data. JS, GS, RS, SO’B, AB, and JL were involved in data curation, and reviewing and editing the manuscript. SNL, HC, KB, and MER were involved in conceptualisation, methodology, supervision, and reviewing and editing the manuscript. All authors had full access to all data in the study, and accept responsibility for the decision to submit for publication.